The role of tumor cell-derived extracellular vesicles in cancer diagnosis and immunotherapies
DOI:
https://doi.org/10.61173/ghv07092Keywords:
Tumor cell-derived extracellular vesicles, Biomarker, ImmunotherapyAbstract
Cancer is a genetic and metabolic disease caused by mutations of genes, dysregulated metabolism, or environmental factors. Since the cancer rate is among the highest in the 20th century and the incidence keeps elevating in the 21st century, it has been expected that 25% of the population will suffer from cancer during their lifetime. However, as the most promising strategy to treat cancer, only 15-20% of patients achieve durable results with immunotherapy. Thus, we still need to find a new therapeutic and detection strategy to make up for the shortcomings of immunotherapy. Tumor cell-derived extracellular vesicles (t-EVs) may be a great helper. This review summarizes the potentials of tumor cell-derived extracellular vesicles used as the cancer biomarkers in cancer early diagnosis and prognostic monitoring and introduces the combined therapy between t-EVs and existing cancer immunotherapies.
References
[1] Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA. Cancer J. Clin. 73, 17–48 (2023). Figure 6. Anti-tumor immune responses induced by C-PMet-
[2] Zhang, Y. & Zhang, Z. The history and advances in cancer based immunometabolic therapy immunotherapy: understanding the characteristics of tumorinfiltrating immune cells and their therapeutic implications. Cell.
[4] Conclusion: Mol. Immunol. 17, 807–821 (2020). T-EVs play an essential role in tumor cell-cell communication 3. Weng, Z. et al. Therapeutic roles of mesenchymal stem celland are involved in a variety of pathological processes. derived extracellular vesicles in cancer. J. Hematol. Oncol.J As an emerging cancer biomarker, t-EVs have a broad Hematol Oncol 14, 136 (2021). potential could be used in cancer targeting therapy. 4. Jia, Y. et al. Small extracellular vesicles isolation and Simultaneously, the strategy of engineered EVs offers an separation: Current techniques, pending questions and clinical opportunity to make up for the shortcomings of traditional applications. 12, (2022). tumor immunotherapy. In this paper, the research progress 5. Gurung, S., Perocheau, D., Touramanidou, L. & Baruteau, of t-EVs biomarkers is reviewed. Representative cases J. The exosome journey: from biogenesis to uptake and analyze the train of thought about engineered t-EVs in intracellular signaling. Cell Commun. Signal. 19, 47 (2021). cancer immunotherapies. However, the research of t-EVs 6. Sheta, M., Taha, E. A., Lu, Y. & Eguchi, T. Extracellular remains to be explored, and some limitations must be Vesicles: New Classification and Tumor Immunosuppression. addressed. Biology 12, 110 (2023). Firstly, the biochemistry of EVs still needs to be entirely 7. Yang, P. et al. Immune Cell-Derived Extracellular Vesicles – determined due to their complexity, like their subtypes, New Strategies in Cancer Immunotherapy. Front. Immunol. 12, and their interaction with target cells16. For instance, 771551 (2021). many studies have found the mediator role of t-EVs. 8. Kalluri, R. & McAndrews, K. M. The role of extracellular However, the specific mechanism of synthesis and release vesicles in cancer. Cell 186, 1610–1626 (2023). is still thoroughly unknown, which could help to develop 9. Lapitz, A. et al. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of Dean&Francis cholangiocarcinoma. J. Hepatol. 79, 93–108 (2023). 16. Liu, C. et al. Engineered extracellular vesicles and their
[10] Yang, P. et al. CD36-mediated metabolic crosstalk between mimetics for cancer immunotherapy. J. Controlled Release 349, tumor cells and macrophages affects liver metastasis. Nat. 679–698 (2022). Commun. 13, 5782 (2022). 17. Morishita, M., Takahashi, Y., Nishikawa, M., Ariizumi, R. &
[11] Tatischeff, I. Extracellular Vesicle-DNA: The Next Liquid Takakura, Y. Enhanced Class I Tumor Antigen Presentation via Biopsy Biomarker for Early Cancer Diagnosis? Cancers 15, Cytosolic Delivery of Exosomal Cargos by Tumor-Cell-Derived 1456 (2023). Exosomes Displaying a pH-Sensitive Fusogenic Peptide. Mol.
[12] Maire, C. L. et al. Genome-wide methylation profiling of Pharm. 14, 4079–4086 (2017). glioblastoma cell-derived extracellular vesicle DNA allows 18. Tian, T. et al. Immune Checkpoint Inhibition in GBM Primed tumor classification. with Radiation by Engineered Extracellular Vesicles. ACS Nano
[13] Zhou, X. et al. Exosomal ncRNAs facilitate interactive 16, 1940–1953 (2022). ‘dialogue’ between tumor cells and tumor-associated 19. Wu, L. et al. Biomimetic Nanocarriers Guide Extracellular macrophages. Cancer Lett. 552, 215975 (2023). ATP Homeostasis to Remodel Energy Metabolism for Activating
[14] Hu, Z. Exosome-derived circCCAR1 promotes CD8 + T-cell Innate and Adaptive Immunity System. Adv Sci (2022). dysfunction and anti-PD1 resistance in hepatocellular carcinoma. 20. Yu, Z.-L. et al. Untouched isolation enables targeted
[2023] . functional analysis of tumour-cell-derived extracellular vesicles
[15] Zhou, Q. et al. Tumor-derived extracellular vesicles in from tumour tissues. melanoma immune response and immunotherapy. Biomed. Pharmacother. 156, 113790 (2022).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
